Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis

European Journal of Cancer

Volumn 86, Issue , 2017, Pages 248-256

  Franklin, Cindy ^a,b,c   Rooms, Isabelle ^a,b   Fiedler, Melanie ^a   Reis, Henning ^a,b   Milsch, Laura ^a,b   Herz, Saskia ^a,b   Livingstone, Elisabeth ^a,b   Zimmer, Lisa ^a,b   Schmid, Kurt Werner ^a,b   Dittmer, Ulf ^a   Schadendorf, Dirk ^a,b   Schilling, Bastian ^a,b,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Checkpoint inhibition; CMV; Colitis; Melanoma

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; VIRUS DNA; ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; COLITIS; COLON BIOPSY; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RELATED DIARRHEA AND COLITIS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; VIRUS REACTIVATION; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; GERMANY; HOST PATHOGEN INTERACTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MELANOMA; OPPORTUNISTIC INFECTION; PATHOGENICITY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SECONDARY; SKIN TUMOR; TIME FACTOR; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTIVIRAL AGENTS; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; GERMANY; HOSPITALS, UNIVERSITY; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MELANOMA; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION; YOUNG ADULT;

EID: 85031825572     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.09.019     Document Type: Article

References (31)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
2. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:17 (2015), 1889–1894.
3. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
4. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
5. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
6. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
7. Weber, J.S., Kahler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
8. Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
9. Berman, D., Parker, S.M., Siegel, J., Chasalow, S.D., Weber, J., Galbraith, S., et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun, 10, 2010, 11.
10. Beck, K.E., Blansfield, J.A., Tran, K.Q., Feldman, A.L., Hughes, M.S., Royal, R.E., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:15 (2006), 2283–2289.
11. Mitchell, K.A., Kluger, H., Sznol, M., Hartman, D.J., Ipilimumab-induced perforating colitis. J Clin Gastroenterol 47:9 (2013), 781–785.
12. Slingerland, M., Nortier, J.W., Veenendaal, R.A., Kapiteijn, E., Severe colitis while responding to ipilimumab in metastatic melanoma. Acta Oncol 51:6 (2012), 805–807.
13. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
14. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5 (2015), 522–530.
15. Rao, M., Valentini, D., Dodoo, E., Zumla, A., Maeurer, M., Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis 56 (2017), 221–228.
16. Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K.R., et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One, 8(5), 2013, e63818.
17. Lankes, K., Hundorfean, G., Harrer, T., Pommer, A.J., Agaimy, A., Angelovska, I., et al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology, 5(6), 2016, e1128611.
18. Uslu, U., Agaimy, A., Hundorfean, G., Harrer, T., Schuler, G., Heinzerling, L., Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 38:5 (2015), 212–215.
19. Maconi, G., Colombo, E., Zerbi, P., Sampietro, G.M., Fociani, P., Bosani, M., et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis 37:6 (2005), 418–423.
20. Minami, M., Ohta, M., Ohkura, T., Ando, T., Ohmiya, N., Niwa, Y., et al. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 13:5 (2007), 754–760.
21. Campos, S.T., Portela, F.A., Tome, L., Cytomegalovirus, inflammatory bowel disease, and anti-TNFalpha. Int J Colorectal Dis 32:5 (2017), 345–350.
22. Kishore, J., Ghoshal, U., Ghoshal, U.C., Krishnani, N., Kumar, S., Singh, M., et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 53:Pt 11 (2004), 1155–1160.
23. Lawlor, G., Moss, A.C., Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. Inflamm Bowel Dis 16:9 (2010), 1620–1627.
24. Rahier, J.F., Magro, F., Abreu, C., Armuzzi, A., Ben-Horin, S., Chowers, Y., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8:6 (2014), 443–468.
25. Romkens, T.E., Bulte, G.J., Nissen, L.H., Drenth, J.P., Cytomegalovirus in inflammatory bowel disease: a systematic review. World J Gastroenterol 22:3 (2016), 1321–1330.
26. Schmidt, C.A., Oettle, H., Peng, R., Neuhaus, P., Blumhardt, G., Lohmann, R., et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 59:8 (1995), 1133–1138.
27. Razonable, R.R., Humar, A., Cytomegalovirus in solid organ transplantation. Am J Transpl 13:Suppl. 4 (2013), 93–106.
28. Kotton, C.N., Kumar, D., Caliendo, A.M., Asberg, A., Chou, S., Danziger-Isakov, L., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:4 (2013), 333–360.
29. McCurdy, J.D., Enders, F.T., Jones, A., Killian, J.M., Loftus, E.V. Jr., Bruining, D.H., et al. Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and How many biopsies?. Inflamm Bowel Dis 21:12 (2015), 2833–2838.
30. Domenech, E., Vega, R., Ojanguren, I., Hernandez, A., Garcia-Planella, E., Bernal, I., et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 14:10 (2008), 1373–1379.
31. Yoshino, T., Nakase, H., Ueno, S., Uza, N., Inoue, S., Mikami, S., et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 13:12 (2007), 1516–1521.